Active Ingredient History

  • Now
Mavoglurant (developmental code name AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome and other conditions which has been discontinued. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGluR5).   Wikipedia

  • SMILES: COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc3cccc(C)c3
  • Mol. Mass: 313.4
  • ALogP: 2.72
  • ChEMBL Molecule:
More Chemistry
afq056 | mavoglurant


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue